ZetrOZ, Inc. of Trumbell, Connecticut, has joined with Singapore-based United BMEC to introduce a wearable device for pain relief. Called sam, for “sustained acoustic medicine, ” the device is claimed by its makers to be the first and only multiple hour bio-electronic wearable device for pain. The firm plans to introduce sam at the medical expo Medica in Frankfurt, Germany.
Acoustic Medicine Device Fights Pain

ZetrOZ officials claim that non-invasive therapeutic technologies have been shown to be more efficient, more portable, and more economically viable than any other ultrasound systems presently available. They state that the sam is currently the world’s smallest and strongest ultrasound therapy system.
The device has been cleared by the Food and Drug Administration and CE marked. The ZetroOZ inventor and chief scientific officer of the firm, George K. Lewis, Ph.D., said, “sam brings ‘first-line’ therapy to acute pain sufferers before that pain becomes chronic. We are working to manage pain and resolve medical conditions for the 1.5 billion sufferers worldwide by introducing doctors, physical therapists, and hospitals to sustained acoustic medicine.”
The device has been tested in clinical trials for treating knee arthritis, upper back and tendonitis pain and is currently undergoing testing by the National Space Biomedical Research Institute for use on astronauts, according to the press release.
Eng Joo, president of United BMEC, said, “Having worked with ZetrOZ since 2009, we are proud to have been an early supporter of this cutting edge technology and to be collaborating in introducing bio-innovative pain technology to the world.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.